http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Biohaven and Pfizer Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea
-
Biohaven's Nurtec® ODT Extends Partnership with Rick Ware Racing for 2022 NASCAR Cup Series and NTT INDYCAR Series
-
Portage Biotech Announces Participation in January 2022 Investor Conferences
-
Biohaven Pharma (BHVN), Pfizer (PFE) Complete Collaboration Transaction for Commercialization of Rimegepant and Zavegepant Outside United States
-
Biohaven and Pfizer Complete Collaboration Transaction for Commercialization of Rimegepant and Zavegepant Outside United States
-
Portage Biotech Announces Financial Results and Provides Business Update for Second Quarter of 2022 Fiscal Year
-
Portage Biotech to Present at the Piper Sandler 33rd Annual Healthcare Conference
-
Portage Biotech Highlights Promising Efficacy and Survival Data Presented on Intensity Therapeutics’ INT230-6 (PORT-1) at November Scientific Conferences
-
Portage Biotech Hosting Key Opinion Leader Webinar on How iNKT Agonists Could Improve Immuno-Oncology Treatment
-
Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States
-
Nine Line Apparel and Biohaven's Nurtec ODT Set to Honor World War II Veterans Ahead of 80th Anniversary at Phoenix Raceway
-
Portage Biotech Announces Participation in September 2021 Investor Conferences
-
Portage Biotech Announces Results for First Quarter of 2022 Fiscal Year
-
Portage Biotech Issues Letter to Shareholders
-
Portage Biotech Highlights First Patient Dosed in IMP-MEL Study of PORT-2 for the Treatment of Melanoma and Non-Small Cell Lung Cancer (NSCLC)
-
Portage Biotech Announces Results for Fiscal Year Ended March 31, 2021
-
Portage Biotech Added to Russell 2000(R) Index
-
Portage Biotech (PRTG) Prices 1M Share Offering at $23/each
-
Portage Biotech Inc. Announces Pricing of Public Offering of 1,000,000 Ordinary Shares
-
Portage Biotech (PRTG) Announces Proposed Share Offering, Size not Disclosed
-
Portage Biotech Inc. Announces Proposed Offering of Ordinary Shares
-
Sosei Heptares Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist Under Collaboration With Biohaven
-
Portage Biotech Highlights Safety and Survival Data from Intensity Therapeutics' IT-01 Study of INT230-6 (PORT-1) at ASCO 2021 Annual Meeting
-
Biohaven's Nurtec® ODT Signs as Primary Partner with Rick Ware Racing for 2021 NTT INDYCAR Series Program
-
Portage Biotech Announces Voluntary Delisting from the Canadian Securities Exchange
-
Portage Biotech Highlights First Patient Dosed in PRECIOUS-01 Study of PORT-3 for the Treatment of NY-ESO-1 Positive Solid Tumors
-
Rick Ware Racing, Biohaven's Nurtec ODT and Nine Line Apparel Honor Fallen Service Members
-
Support.com Appoints Lowell Robinson and Elizabeth Fetter to Board of Directors

